Thanks for the info. Great to hear that they are still planning on releasing the histology and cytokine data. I was starting to think they were going to backtrack on the previous PR and hold it until presenting the results next year.
This data is going to reveal much more than the echo data did. The current results would lead me to believe that key biologics were activated but it does nothing to show whether the device promoted regeneration of damaged tissue or prevention of necrosis and scarring.
What the device did with the functionality of the heart is astounding in and of itself but if they show regeneration we are talking a truly unprecedented result. I have said it before here but what they have looked to do here is what the great, and after 20+ years, yet unfulfilled promise of traditional stem cell therapies has failed to do, regrow damaged heart tissue.
I think what Steve is saying when he says they are not overly concerned about the share price right now is simply that it is not going to stay here. Anyone with any knowledge of what is happening with this company should know this. We may be impatient, we may want more communication, but we all know where this is headed.
I have had to check myself the last couple of days remembering that when I first got into ENDV it was on little more than hope and optimism. Now we have results! Once this final data is released and the medical world can access and weigh in on the data things will change fast.
Then comes the next 3 trial results!!!
Thanks again for taking the time to get in touch with Steve.
News 
Market Data 
Discover 
